MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

United Therapeutics Corp

Abrir

SetorSaúde

289.69 -1.9

Visão Geral

Variação de preço das ações

24h

Atual

Mín

286.55

Máximo

297.62

Indicadores-chave

By Trading Economics

Rendimento

-7.8M

301M

Vendas

-13M

736M

P/E

Médio do Setor

11.884

57.333

EPS

6.19

Margem de lucro

40.943

Funcionários

1,305

EBITDA

6.3M

424M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+29.27% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.4B

13B

Abertura anterior

291.59

Fecho anterior

289.69

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

United Therapeutics Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2024, 15:14 UTC

Grandes Movimentos do Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 de jan. de 2025, 10:30 UTC

Principais Notícias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparação entre Pares

Variação de preço

United Therapeutics Corp Previsão

Preço-alvo

By TipRanks

29.27% parte superior

Previsão para 12 meses

Média 383.18 USD  29.27%

Máximo 460 USD

Mínimo 293 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para United Therapeutics Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

285.09 / 298.295Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.